Medicine procurement and the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001–2016

  title={Medicine procurement and the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001–2016},
  author={Ellen F M 't Hoen and Jacquelyn Dietrich Veraldi and Brigit Toebes and Hans V. Hogerzeil},
  journal={Bulletin of the World Health Organization},
  pages={185 - 193}
Abstract Millions of people, particularly in low- and middle-income countries, lack access to effective pharmaceuticals, often because they are unaffordable. The 2001 Ministerial Conference of the World Trade Organization (WTO) adopted the Doha Declaration on the TRIPS (Trade-Related Aspects of Intellectual Property Rights) Agreement and Public Health. The declaration recognized the implications of intellectual property rights for both new medicine development and the price of medicines. The… Expand
A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications
An interdisciplinary review of the patent status of EML cancer medicines compared to other EML noncommunicable disease medicines using the 17th, 18th, 19th, 20th, and 21st editions of the list concludes that patent status is simply one factor in the complex international environment of health systems, IPR policies, and trade regimes. Expand
Patent challenges in the procurement and supply of generic new essential medicines and lessons from HIV in the southern African development community (SADC) region.
15 instances of the use of TRIPS flexibilities by eight SADC Member States during the period 2001–2016 concerned least developed countries that declared non-enforcement of pharmaceutical patents pursuant to a new LDC transition provision, all of which occurred in the context of medicines procurement for HIV treatment. Expand
Patents, trade and medicines: past, present and future
Abstract This article analyzes the spread of intellectual property in trade agreements. We explain how the integration of intellectual property with international trade rules led to the globalizationExpand
Pharmaceutical patents: reconciling the human right to health with the incentive to invent
The human rights implication of providing access to all cancer drugs recommended by experts in a developed country is considered in the context of conflict between the incentive to invent and the rights of others to access medicines. Expand
Health Services and Access to Medicines and Other Health Technologies
This chapter explores the implications of trade agreements for the provision of health services and access to medicines and other health technologies. It first examines the potential effects of theExpand
Rising Cancer Drug Prices: What Can Low- and Middle-income Countries Do?
There is ample room for effective intervention: joint price negotiations, cost transparency, greater support for creation of manufacturing capacity, and regulatory measures that facilitate introduction of generic and biosimilar drugs and reduce intellectual property barriers to better use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights. Expand
Global equitable access to vaccines, medicines and diagnostics for COVID-19: The role of patents as private governance
It is argued that the extent of control currently given to patent holders for COVID-19 must be questioned and that patents have significant implications for healthcare acting as private governance tools over patented inventions. Expand
Importance of the intellectual property system in attempting compulsory licensing of pharmaceuticals: a cross-sectional analysis
  • K. Son
  • Business, Medicine
  • Globalization and Health
  • 2019
Evidence of an association between attempting compulsory licensing and matured patent systems is provided by demonstrating that countries with a mature patent system were more likely to utilize compulsory licensing of pharmaceuticals. Expand
USMCA (NAFTA 2.0): tightening the constraints on the right to regulate for public health
The USMCA places new, extended, and enforceable obligations on public regulators that increase the power of corporate (investor) interests during the development of new regulations and is not a health-enhancing template for future trade agreements that governments should emulate. Expand
Anti Pharmaceutical Patent Ever-greening Law: Global Need in Support of Public Health
Drug patenting would be an effective tool to encourage introducing new drugs for prevention and treatment of diseases. The main goal of drug patenting is to protect all the interests of inventor andExpand


Implications of bilateral free trade agreements on access to medicines.
  • C. Correa
  • Medicine
  • Bulletin of the World Health Organization
  • 2006
A recent new wave of free trade agreements requires even higher levels of intellectual property protection for medicines than those mandated by that Agreement, which further limit the competition of generic products. Expand
Initiatives to challenge patent barriers and their relationship with the price of medicines procured by the Brazilian Unified National Health System.
The historical series of the price of lopinavir/ritonavir (LPV/r) in Brazil and in the international market is analyzed considering the initiatives to challenge patent barriers between 2001 and 2012 and results show that there was a 30% reduction in the Brazilian purchasing price. Expand
A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries
Indian generic producers supply the majority of ARVs in developing countries, and future scale up using newly recommended ARVs will likely be hampered until Indian generic producers can provide the dramatic price reductions and improved formulations observed in the past. Expand
Driving a decade of change: HIV/AIDS, patents and access to medicines for all
Since 2000, access to antiretroviral drugs to treat HIV infection has dramatically increased to reach more than five million people in developing countries, a result of global political mobilization that cleared the way for competitive production of generic versions of widely patented medicines. Expand
Industry-Led Access-To-Medicines Initiatives In Low- And Middle-Income Countries: Strategies And Evidence.
It is clear that the biopharmaceutical industry has increased its commitment to improving access to medicines in low- and middle-income countries, however, companies should do more to generate high-quality evidence on their initiatives, and the global health community shouldDo more to assist the developing of evidence about the initiatives. Expand
'Government Patent Use': A Legal Approach To Reducing Drug Spending.
It is proposed that the federal government invoke its power under an existing "government patent use" law to reduce excessive prices for important patent-protected medicines. Expand
Indian hepatitis C drug patent decision shakes public health community
The grant of the sofosbuvir patent to Gilead does not mean that generic production and supply are impossible, but it does mean that people with HCV will have easy access to low cost medicines. Expand
The new political economy of pharmaceuticals : production, innovation and TRIPS in the global south
1. The New Political Economy of Pharmaceuticals: Conformity and Resistance in the Global South Owain David Williams and Hans Lofgren 2. The Political Economy of Pharmaceutical Production in BrazilExpand
The Doha Declaration on the TRIPS Agreement and Public Health: Lighting a Dark Corner at the WTO
The adoption by Ministers on 14 November 2001, in Doha, of the Ministerial Declaration on the TRIPS Agreement and Public Health marked a turning point in political and legal relations at the WTO.Expand
TRIPS and New Challenges for the Pharmaceutical Sector in South Korea
The South Korean economy has been growing over the past five decades at an average annual rate of 6.2 per cent. In 2011 gross domestic product (GDP) per capita was US$20,870 (World Bank, 2012). TheExpand